Characterizing Advanced Parkinson’s Disease: Romanian Subanalysis from the OBSERVE-PD Study
Table 4
Actual conventional treatments. APD versus non-APD.
Variable
APD (n= 95)
Non-APD (n= 66)
Treatment type,a,bn (%)
Oral levodopa + carbidopa or benserazide
80 (84.2)
50 (75.8)
0.22
MAOB inhibitor
53 (55.8)
29 (43.9)
0.15
Oral dopamine agonist(s)
36 (37.9)
34 (51.5)
0.11
COMT inhibitor
27 (28.4)
0 (0)
<0.0001
Amantadine
27 (28.4)
4 (6.1)
<0.001
Otherc medication
22 (23.2)
12 (18.2)
0.56
Mean number of standard treatments/patients
2.58
1.95
<0.001
1 treatment, n (%)
14 (14.7)
14 (21.2)
2 treatments, n (%)
28 (29.5)
29 (43.9)
3 treatments, n (%)
24 (25.3)
19 (28.8)
4 treatments, n (%)
17 (17.9)
0 (0)
5 treatments, n (%)
7 (7.4)
0 (0)
No treatment specified,dn (%)
5 (5.3)
4 (6.1)
APD: advanced Parkinson’s disease; COMT: catechol-o-methyltransferase; and MAOB: monoamine-oxidase B. aNo data available for 5 APD and 4 non-APD patients, respectively; bmultiple entries were possible; cincluding dopamine agonist patch; and dno treatment specified/missing information. Statistically significant values (0.05) are presented in bold.
